This study tests if a drug called Xanamem® helps people with early Alzheimer's Disease (AD) or Major Depressive Disorder (MDD). Alzheimer's is a brain disease that affects memory, and depression is a mental health problem. The study will test Xanamem's safety and effectiveness in people with mild to moderate dementia due to AD. Participants will be randomly given either 10 mg of Xanamem or a placebo (a pill with no medicine) for 36 weeks. Neither participants nor doctors will know who gets the real medicine, which is called a "double-blind" study.
- Study Length: The study lasts for 36 weeks, with visits up to 11.5 months.
- Eligibility: Participants must be 50 or older, have mild/moderate dementia, and cannot have certain other health issues.
- Participation: Participants need a study partner to help with assessments and provide information.
If you want to join, you should be ready to stop caffeine for 4 hours and nicotine for 2 hours before tests. You must not have used certain medications or participated in other studies recently. Participants will sign a consent form to show they understand and agree to join this study.